Zhi Guoguo, Shao Bingjie, Zheng Tianyan, Mu Jie, Li Jingwei, Feng Yiyuan, Zhu Sha, Dang Yanni, Liu Feng, Wang Dong
School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Shanxi Buchang Pharmaceutical Company Limited, Xi'an, Shanxi, China.
Front Pharmacol. 2023 Jan 24;14:1082451. doi: 10.3389/fphar.2023.1082451. eCollection 2023.
With the gradual increase in prevalence in recent years, non-alcoholic steatohepatitis (NASH) has become one of the significant health problems that urgently needs to be addressed worldwide. GanShuang Granules (GSG) is derived from the classical Chinese formula Xiaoyao San and mainly used in the clinical treatment of chronic liver diseases. In this study, we aim to gain a deeper insight into the inhibiting effects of GSG on non-alcoholic fatty liver disease (NAFLD) rats and preliminarily elucidate the underlying intervention mechanisms. First, High performance liquid chromatography (UHPLC-Q/Orbitrap-MS/MS) was used for the active compounds prediction in GSG. Then the data was mapped to mzCloud database. The targets corresponding to GSG compounds were collected from public databases, along with disease genes for NAFLD. The core targets and molecular mechanisms of GSG for NAFLD treatment were predicted by protein-protein interaction (PPI) network, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses. Molecular docking of the core target-component interactions was simulated using AutoDock Vina software. The effect of GSG on NASH rats was evaluated by pathological staining and analysis of various index results. Finally, the candidate targets were further validated by ELISA and western blot (WB) analyses. Combining UHPLC-Q/Orbitrap-MS/MS data analysis and public database data, a total of 346 cross-targets were obtained, corresponding to 81 compounds. The subnetwork with an MCODE score of 53.623 is a potential core target group for this study. GO and KEGG enrichment analyses showed that the targets of GSG in NAFLD were mostly related to oxidative stress, the NF-κB signaling pathway, and the apoptosis signaling pathway. By integrating the results of network pharmacology analysis, the core objectives of this study mainly include and . The core ingredients are related to resveratrol and fisetin. The molecular docking results indicated key binding activity between AKT1-fisetin, AKT1-Resveratrol, and CASP8-fisetin. Moreover, GSG could improve the inflammatory status and restore the abnormal lipid accumulation of NAFLD/NASH liver, and these levels are further verified by pathological staining and detection of related indicators. Mechanistically, GSG could regulate protein expression levels in the liver for P65, p-P65, IKB, p-IKB, IKK, caspase-3, -8, -9, and cytochrome C, etc. It reflects the inhibitory effect of GSG on the NF-κB/IκB signaling pathway. Our results suggested that GSG demonstrated therapeutic effects on NAFLD/NASH rats, and these may be mainly reflected in the inhibitory effects on the NF-κB/IκB signaling pathway and its downstream inflammation and apoptosis signals.
近年来,随着非酒精性脂肪性肝炎(NASH)患病率的逐渐上升,它已成为全球迫切需要解决的重大健康问题之一。肝爽颗粒(GSG)源自经典中药方剂逍遥散,主要用于慢性肝病的临床治疗。在本研究中,我们旨在更深入地了解GSG对非酒精性脂肪性肝病(NAFLD)大鼠的抑制作用,并初步阐明其潜在的干预机制。首先,采用超高效液相色谱-四极杆/静电场轨道阱高分辨质谱联用技术(UHPLC-Q/Orbitrap-MS/MS)对GSG中的活性成分进行预测。然后将数据映射到mzCloud数据库。从公共数据库中收集与GSG化合物对应的靶点以及NAFLD的疾病基因。通过蛋白质-蛋白质相互作用(PPI)网络、基因本体论(GO)和京都基因与基因组百科全书(KEGG)功能富集分析预测GSG治疗NAFLD的核心靶点和分子机制。使用AutoDock Vina软件模拟核心靶点-成分相互作用的分子对接。通过病理染色和各项指标结果分析评估GSG对NASH大鼠的影响。最后,通过酶联免疫吸附测定(ELISA)和蛋白质免疫印迹法(WB)分析进一步验证候选靶点。结合UHPLC-Q/Orbitrap-MS/MS数据分析和公共数据库数据,共获得346个交叉靶点,对应81种化合物。MCODE评分为53.623的子网是本研究的潜在核心靶点组。GO和KEGG富集分析表明,GSG在NAFLD中的靶点大多与氧化应激、NF-κB信号通路和凋亡信号通路相关。综合网络药理学分析结果,本研究的核心目标主要包括 和 。核心成分与白藜芦醇和非瑟酮有关。分子对接结果表明AKT1-非瑟酮、AKT1-白藜芦醇和CASP8-非瑟酮之间存在关键结合活性。此外,GSG可改善NAFLD/NASH肝脏的炎症状态并恢复异常脂质蓄积,这些水平通过病理染色和相关指标检测得到进一步验证。从机制上讲,GSG可调节肝脏中P65、p-P65、IKB、p-IKB、IKK、半胱天冬酶-3、-8、-9和细胞色素C等蛋白的表达水平。这反映了GSG对NF-κB/IκB信号通路的抑制作用。我们的结果表明,GSG对NAFLD/NASH大鼠具有治疗作用,这些作用可能主要体现在对NF-κB/IκB信号通路及其下游炎症和凋亡信号的抑制作用上。